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HepatectomyAbstract Purpose: Patient outcome after resection of colorectal liver metastases (CLM)
following second-line preoperative chemotherapy (PCT) performed for insufficient response
or toxicity of the first-line, is little known and has here been compared to the outcome
following first-line.
Patients and methods: From January 2005 to June 2013, 5624 and 791 consecutive patients of
a prospective international cohort received 1 and 2 PCT lines before CLM resection (group 1
and 2, respectively). Survival and prognostic factors were analysed.
Results: After a mean follow-up of 30.1 months, there was no difference in survival from CLM
diagnosis (median, 3-, and 5-year overall survival [OS]: 58.6 months, 76% and 49% in group 2
versus 58.9 months, 71% and 49% in group 1, respectively, P Z 0.32). After hepatectomy,
disease-free survival (DFS) was however shorter in group 2: 17.2 months, 27% and 15% versus
19.4 months, 32% and 23%, respectively (P Z 0.001). Among the initially unresectable pa-
tients of group 1 and 2, no statistical difference in OS or DFS was observed. Independent pre-
dictors of worse OS in group 2 were positive primary lymph nodes, extrahepatic disease,
tumour progression on second line, R2 resection and number of hepatectomies/year <50. Pos-
itive primary nodes, synchronous and bilateral metastases were predictors of shorter DFS.
Initial unresectability did not impact OS or DFS in group 2.
Conclusion: CLM resection following second-line PCT, after oncosurgically favourable selec-
tion, could bring similar OS compared to what observed after first-line. For initially unresect-
able patients, OS or DFS is comparable between first- and second-line PCT. Surgery should
not be denied after the failure of first-line chemotherapy.
ª 2017 Elsevier Ltd. All rights reserved.1. Introduction scarcely described. Its impact on survival is not yetLiver resection is the only treatment that currently of-
fers a chance of long-term survival to patients with
colorectal liver metastases (CLM). For patients with
primarily resectable CLM, especially those with
advanced, multiple or borderline resectable disease,
perioperative systemic chemotherapy has been given to
increase their long-term survival by reducing the risk of
recurrence after resection. However, the majority of
patients with CLM are not initial candidates for hepatic
resection. Without conversion chemotherapy, surgical
resection is not possible for 70%e80% of those patients.
Encouragingly, the combination of systemic chemo-
therapy and liver surgery could switch a significant
proportion of patients from a palliative to a potentially
curative situation, with a reported postoperative 5-year
survival of 33% after rescue surgery [1e3]. Recently, an
international panel of multidisciplinary experts devel-
oped recommendations for the management of patients
with CLM, indicating that preoperative treatment to
induce resectability should be as short as possible, and
that postoperative chemotherapy (POCT) should
continue with the same protocol when preoperatively
effective [4].
Failure to respond to first-line therapy has frequently
predicted poor response rates of subsequent lines of
therapy [5e7]. For patients where disease control is the
goal, patients should proceed to second-line therapy
when there is evidence of disease progression, or toxicity
of the first-line [8]. However, the combination of
second-line systemic chemotherapy (for neoadjuvant or
conversion purpose) with CLM resection has beendemonstrated, and what kind of patients can really
benefit from the resection is so far unknown. In this
study, we aimed to analyse the impact of the CLM
resection after second-line treatment, in terms of overall
survival (OS) and disease-free survival (DFS) in a
large international dataset, and to find out the predic-
tive factors of outcomes for such patients. The survival
data were also compared to that of the CLM resection
following first-line chemotherapy, in the same onco-
surgical teams, although the two cohorts were not
rigorously comparable.2. Patients and methods
2.1. Patient selection
LiverMetSurvey is a prospective international internet-
based registry, collecting and regularly updating clinical
data from all consecutive patients undergoing surgery
for CLM, and was designed to assess the efficacy of
multimodality treatment of CLM [3]. It accounted on
25th December 2015, with 243 individual patients from
313 institutions worldwide (70 countries). In this study,
the data of 6415 consecutive patients were retrospec-
tively analysed. Between January 2005 and June 2013,
5624 patients underwent resection after first-line
chemotherapy (group 1) and 791 patients following
second-line chemotherapy (group 2), respectively.
Patient eligibility criteria included the completion of
hepatic resection with intent to resect all the metastases,
irrespective of the initial resectability of CLM and of the
R. Adam et al. / European Journal of Cancer 78 (2017) 7e15 9need for specific combined techniques to optimise
resectability after first- or second-line preoperative
chemotherapy (PCT). In this study, we defined a second-
line regimen when the first-line cytotoxic backbone had
changed, or when a biological agent had been added.
Patients receiving second-line because of intolerable
toxicity were included because this situation is not rare
in clinical practice, although toxicity does not reflect the
tumour response to chemotherapy. The initially unre-
sectable patients in group 1 were classified into sub-
group 1, and such patients in group 2 into subgroup
2 for additional subgroup analyses.
Patients, on whom an R2 resection was performed,
although considered surgically unsatisfactory, were
included in the analysis since we adopted an intent-to-
treat policy on such patients, as in real-life situations.
2.2. Preoperative management
Generally, the response to chemotherapy was evaluated
every four cycles with computed tomography (CT)
according to the Response Evaluation Criteria in Solid
Tumours Criteria (RECIST) [9]. In each centre, pa-
tients were evaluated from referral by the same local
multidisciplinary team, who determined when to start a
chemotherapy with neoadjuvant or conversion intent,
when to perform liver resection and when to switch to
second-line PCT, in case of progression, or insufficient
response (stable disease or partial response unable to
allow complete or safe resection) or in case of unac-
ceptable toxicity on first-line regimen. Generally, as an
accepted clinical practice, for the patients with poten-
tially resectable CLM but with advanced, multiple or
borderline resectable disease, neoadjuvant chemo-
therapy was proposed with the intent to increase
survival.
2.3. Hepatic resection
The overall policy of hepatectomy was carried out with
the attempt of a complete resection of all lesions by
anatomic or wedge resection, sparing the largest amount
of hepatic parenchyma but providing as much as
possible a safe margin of normal parenchyma from the
tumour. Radiofrequency ablation was combined with
hepatectomy whenever appropriate in treating unre-
sectable remnant lesions limited in number (3) and size
(<3 cm). Two-stage hepatectomy was reserved for the
patients whose disease was deemed unresectable by a
single procedure. Other combined techniques including
portal vein embolisation were also employed.
2.4. Postoperative chemotherapy
POCT was routinely used after hepatectomy, with the
same regimen when preoperatively effective.2.5. Follow-up
Patients were usually followed one month later after the
resection, then every 3e6 months according to the centre
policy, with tumour markers (carcinoembryonic antigen
and carbohydrate antigen 19.9), clinical examination,
thoracic and hepatic imaging (ultrasound and/or CT and/
or magnetic resonance imaging). Repeat resection of
intrahepatic recurrence or extrahepatic disease was per-
formedby the local surgical teamwhenpotentially curative.
2.6. Statistical analysis
Survival was calculated from CLM diagnosis and from
hepatectomy to death or to the last available follow-up.
Patient survival probabilities were determined by the
life-table method and compared in the log-rank test. A
multivariate Cox proportional hazard model with a
likelihood ratio test was used to identify predictive fac-
tors for OS (from CLM diagnosis) and DFS. According
to RECIST, tumour responses after first- or second-line
chemotherapy were classified into either progression or
no progression for multivariate model. Statistical ana-
lyses were performed with SAS software version 9.1.3
(SAS Institute Inc., Cary, NC, USA).
3. Results
Overall, 5624 patients (87.7%) and 791 patients (12.3%)
received CLM resection after 1 and 2 PCT lines (group 1
and group 2), respectively. The incidences of CLM
resection by year following 1 and 2 PCT lines are shown
in Supplementary Fig. A1.
3.1. Patient and tumour characteristics
The clinical characteristics of the study population
are shown in Table 1, together with comparisons
between groups, and between initially unresectable
subgroups.
3.2. Chemotherapy data
Supplementary Table A1 presents the PCT regimens
used in the two groups. Doublet regimens were admin-
istered to 63.4% of the patients in second-line, triplet
regimens were used to 3.6%, and monoclonal antibodies
were given to 33.0% of these patients. Compared to the
first-line PCT in group 1, the second-line PCT in group 2
included more often irinotecan-based regimen and
combination with cetuximab or panitumumab.
In group 2, patients received a median of six (inter-
quartile range [IQR], 4e9) cycles of first-line chemo-
therapy. The causes for switching to second-line were
disease progression (22.2%), stable disease (22.7%),
insufficient partial response (48.1%) or intolerable toxicity
Table 1
Comparison of clinical features of the study population.










Female, % 39.2 34.9 0.019 39.5 34.5 NS
Age, mean (SD), year 61.6 (10.7) 61.4 (10.6) NS 60.5 (11.1) 60.4 (10.2) NS
Primary tumour localisation, %
Left including sigmoid 42.6 48.3 0.049 47.0 53.8 NS
Rectum 32.5 29.7 29.6 26.4
Right 18.0 16.4 16.6 14.6
Transverse 3.5 2.7 4.0 2.4
Multiple localisations 3.3 2.9 2.7 2.8
Metastatic primary lymph nodes, % 67.8 68.4 NS 66.7 66.4 NS
Concomitant extrahepatic disease, % 12.2 16.7 <0.001 14.8 21.7 0.003
Interval between disease diagnosis and liver
metastasis occurrence, mean (SD), months
7.1 (18) 5.5 (12.3) 0.002 5.9 (17.6) 4.7 (10.4) NS
No. of liver metastasis at diagnosis, %
1e3 69.7 62.9 <0.001 49.0 46.7 NS
4e7 21.9 25.7 30.1 30.3
>7 8.4 11.3 20.9 23.0
Metastasis at diagnosis 30 mm, % 43.5 38.7 0.023 34.0 28.5 NS
Liver metastases, %
Synchronous 70.9 73.5 NS 77.2 77.0 NS
Bilateral localisation 46.9 54.1 <0.001 68.0 67.7
Initially unresectable 32.9 41.8 <0.001 100.0 100.0
Main causes of non-resectability, %
Number of metastases e e e 43.7 50.8 NS
Size of metastases e e 18.4 15.2
Vascular ill location e e 17.5 13.6
Extrahepatic disease e e 9.9 11.4
Others e e 10.5 9.1
Preoperative chemotherapy cycles
1e6 cycles, % 62.9 17.6 <0.001 49.8 12.6 <0.001
No., median [IQR] 6 [4e8] 12 [8e16] <0.001 7 [5e10] 13 [9e18] <0.001
Response to PCT last-line, %
Complete response 5.4 5.0 <0.001 3.9 4.7 <0.001
Partial response 69.0 61.5 81.2 66.1
Stable disease 19.3 25.1 11.0 22.6
Progression 6.2 8.4 3.9 6.6
Limited hepatectomy (<3 segments), % 38.4 33.0 0.004 31.4 26.7 NS
R0þR1 liver resection, % 88.1 82.8 <0.001 76.0 72.7 NS
Hepatectomy not globally curative, % 20.6 26.1 <0.001 35.9 38.4 NS
Combined techniques, % 28.1 37.8 <0.001 56.0 47.2 0.006
Portal vein embolisation, % 14.1 23.8 <0.001 24.9 35.3 <0.001
Radiofrequency ablation, % 11.3 13.4 NS 15.4 15.4 NS
Cryotherapy, % 0.1 0 NS 0.1 0 NS
Two-stage hepatectomy, % 11.2 14.5 0.008 21.7 23.5 NS
Only one hepatectomy, % 83.0 79.4 <0.001 79.3 74.4 0.004
No. of hepatectomies/year 50, % 45.3 54.7 <0.001 36.7 49.3 <0.001
POCT, % 58.3 58.2 NS 57.8 56.6 NS
Cycles, median [IQR] 6 [4e8] 6 [4e9] NS 6 [4e8] 6 [3e12] NS
90-d postoperative mortality, % 2.7 2.4 NS 3.9 4.3 NS
Postoperative complications, % 29.9 33.5 0.044 35.0 38.7 NS
PCT, preoperative chemotherapy; SD, standard deviation; IQR, interquartile range; POCT, postoperative chemotherapy; NS, not significant.
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accepted reason for non-operating patients after first-line
chemotherapy. In case of stable disease or partial
response, the main consideration was better disease con-
trol before surgery for initially resectable patients or
adequate conversion to allow complete and safe resection
for initially unresectable patients. In second-line, these
patients received amedian of five (IQR, 3e8) preoperativecycles of therapy. Furthermore, 58.2% of group 2 patients
received POCT (second-line regimen), and 9.5% received
later a third-line for relapse. Conversely, 58.3% of group 1
patients received POCT (first-line regimen), 5.3% received
later second-line for relapse and 1.2% a third-line.
In subgroup 2, patients received a median of six
(IQR, 4e11) cycles of first-line chemotherapy with
21.5% progression and 56.9% insufficient objective
R. Adam et al. / European Journal of Cancer 78 (2017) 7e15 11response. After a median of six (IQR, 3e9) cycles of
second-line, this subgroup experienced 6.6% progression
and 70.8% objective response (P < 0.001).
3.3. Mortality and morbidity
After hepatectomy, the 90-d mortality was 2.4% in
group 2 versus 2.7% in group 1 (P Z 0.618), and the
morbidity was 33.5% versus 29.9%, respectively
(P Z 0.044). For the initially unresectable patients, the
mortality was similar between the subgroups and so was
the morbidity (Table 1).
3.4. Overall survival
After a mean follow-up of 30.1 months, in group 2
(n Z 777) and group 1 (n Z 5456), median OS afterFig. 1. OS and DFS of CLM patients received liver resection following
and DFS (D) after first hepatectomy of CLM after PCT; OS (C) after m
to cause for chemotherapy change. OS, overall survival; DFS, disease-
chemotherapy; DP, disease progression; PR, partial response.diagnosis was 58.6 months (95% confidence interval,
52.0e63.2 months) versus 58.9 months (56.0e60.9), 3-
year OS rate was 76% (72%e79%) versus 71% (70%e
73%) and 5-year OS was 49% (43%e54%) versus 49%
(47%e51%), respectively (P Z 0.32; Fig. 1A). After the
first hepatectomy, in group 2 (n Z 785) and group 1
(nZ 5567), median OS was 41.4 (39.2e46.8) versus 49.0
months (46.5e51.5), 3-year OS was 60% (55%e65%)
versus 62% (60%e64%) and 5-year OS was 35% (29%e
42%) versus 43% (41%e45%), respectively (P Z 0.049;
Fig. 1B).
For patients initially unresectable, no statistical dif-
ference appeared in OS after diagnosis or after the first
hepatectomy (Supplementary Figs. A2 and A3A) be-
tween the subgroups of patients resected after first-line
and second-line conversion chemotherapy.PCT. OS (A) after diagnosis of CLM resected after PCT; OS (B)
etastatic diagnosis of CLM resected after 2nd-line PCT according
free survival; CLM, colorectal liver metastases; PCT, preoperative
R. Adam et al. / European Journal of Cancer 78 (2017) 7e1512Regarding the impact of the reasons leading to a
second-line regimen, OS of progression was similar to
that of stable disease but lower compared to that of
insufficient partial response or toxicity. Toxicity seemed
to be associated with a higher OS than stable disease but
not than partial response. No survival difference existed
between stable disease and partial response (Fig. 1C).
3.5. Disease-free survival
Median, 3-year and 5-year DFS after first macroscopi-
cally complete hepatectomy were statistically lower in
group 2 (17.2 months, 27% and 15%; n Z 551) than
those in group 1 (19.4 months, 32% and 23%; nZ 4171;
P Z 0.01; Fig. 1D). For initially unresectable patients,
no statistical difference in DFS was observed between
subgroup 2 and subgroup 1 (median, 3- and 5-year: 18.1
months, 28% and 14% versus 19.7 months, 32% and
22%; P Z 0.09; Supplementary Fig. A3B).
Concerning the impact of the different causes of
second-line inclusion, no statistical difference in DFS
was observed (data not shown).
3.6. Analysis of predictive factors
3.6.1. Overall survival
By multivariate analysis, five factors were independently
associated with decreased OS (Table 2). Progressive
disease on first-line chemotherapy was associated with
worse OS after diagnosis at univariate but not at
multivariate analysis, in the studied second-line setting
(Fig. 1C). For subgroup 2, in the multivariate model,
four independent factors were associated with worse OSTable 2
Analysis of OS after metastasis diagnosis in 2 PCT lines patients and its in
Risk factors All patients with 2 PCT lines (n Z 777)
3 years 5 years Univariate Multivariate
P-value P-value HR (95% CI)
Metastatic primary lymph nodes
Yes 73% 41% 0.002 0.018 1.54 (1.08e2.19
No 83% 63%
Concomitant extrahepatic disease
Yes 65% 35% <0.001 0.016 1.58 (1.09e2.29
No 78% 52%
Second-line tumour progression
Yes 69% 45% 0.120 0.016 1.75 (1.11e2.77
No 76% 49%
Liver curative resection
R2 56% 25% <0.001 <0.001 2.72 (1.86e3.96
R0/R1 81% 54%
No. of hepatectomies/year
<50 72% 43% <0.001 0.002 1.67 (1.20e2.33
50 79% 55%
Postoperative chemotherapy
No 70% 47% 0.290 e
Yes 79% 49%
PCT, preoperative chemotherapy; HR, hazard ratio; CI, confidence interv(Table 2). The separate number (6 or >6) of cycles
received in first- or second-line did not impact OS in
group 2 nor in its unresectable subset (subgroup 2).
3.6.2. Disease-free survival
Among group 2 patients with R0/R1 liver resection, the
multivariate analysis showed that metastatic lymph
nodes, synchronous and bilateral metastases were asso-
ciated with decreased DFS. Progression on first-line
chemotherapy was not predictive for shorter DFS. In
this model for subgroup 2 patients, three factors asso-
ciated with decreased DFS were bilateral metastases, no
POCT and radiofrequency combined with hepatectomy
(Table 3).
4. Discussion
In this study, we observed, in a large international and
prospective database, that the outcomes of patients with
CLM eventually undergoing resection after second-line
PCT were mostly similar to those obtained after first-
line PCT, although these two cohorts were not strictly
comparable because disease was more extensive in the
former. Indeed, not surprisingly, these patients had a
statistically heavier tumour burden, a poorer response to
treatment and more complex surgical treatments,
compared to the patients resected after first-line. From
first-line to second-line, the switch offered a better
tumour control to these patients, allowing a significantly
decreased progression rate from 22.2% to 8.4% and an
increased objective response rate from 55.1% to 66.5%.
Thus, surgery was offered with more stringent criteria of
tumour response to patients after second-lineitially unresectable subgroup.
Initially unresectable patients with 2 PCT lines (n Z 283)
3 years 5 years Univariate Multivariate
P-value P-value HR (95% CI)
) 69% 44% 0.440 e
76% 48%
) 62% 34% 0.009 0.005 2.10 (1.25e3.51)
74% 48%
) 65% 55% 0.870 e
72% 44%
) 53% 27% 0.011 0.002 2.65 (1.44e4.86)
78% 51%
) 68% 39% 0.003 0.004 2.49 (1.35e4.62)
75% 52%
66% 35% 0.009 <0.001 2.30 (1.42e3.72)
80% 55%
al; OS, overall survival.
Table 3
Analysis of DFS in the R0/R1 2 PCT lines patients and its initially unresectable subgroup.
Risk factors All patients with 2 PCT lines (n Z 551) Initially unresectable patients with 2 PCT lines (n Z 167)
3 years 5 years Univariate Multivariate 3 years 5 years Univariate Multivariate
P-value P-value HR (95% CI) P-value P-value HR (95% CI)
Metastatic primary lymph nodes
Yes 23% 15% 0.020 0.020 1.39 (1.05e1.82) 24% 9% 0.220 e
No 40% 19% 36% 18%
Synchronous metastasis
Yes 25% 17% 0.033 0.043 1.36 (1.01e1.82) 26% 17% 0.600 e
No (metachronous) 34% 14% 29% 9%
Bilateral localisation
Yes 21% 13% 0.002 0.018 1.36 (1.05e1.75) 21% e 0.024 0.047 1.60 (1.01e2.55)
No 34% 17% 34% 24%
Radiofrequency ablation
Yes 20% 13% 0.009 NS 13% e <0.001 0.008 2.09 (1.21e3.61)
No 30% 16% 30% 18%
Postoperative chemotherapy
Yes 29% 16% 0.026 NS 32% 16% 0.010 0.024 1.68 (1.07e2.62)
No 20% 10% 15% e
PCT, preoperative chemotherapy; HR, hazard ratio; CI, confidence interval; NS, not significant; DFS, disease-free survival.
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teristics in such patients, OS from CLM diagnosis was
similar, whether hepatectomy was performed after first-
or second-line chemotherapy. However, surgery after
second-line was associated with a decreased OS and
DFS after hepatectomy in comparison to first-line.
Usually patients with CLM receiving second-line
chemotherapy and then hepatectomy are expected to
have a poorer prognosis, hence the rationale to
perform resection is questioned. A retrospective study
reported a 5-year OS after hepatectomy following
second-line of 22% and a 5-year DFS of only 11% [10].
In our multicentre study, however, such patients
(group 2) displayed relatively better results. After
hepatectomy, the median and 5-year figures were 41.4
months and 35% for OS and 17.2 months and 15% for
DFS, respectively. Moreover, the median and 5-year
OS after diagnosis were 58.6 months and 49%,
respectively, not significantly different from those
observed in group 1. One recent meta-analysis has
shown a respective median and 5-year OS of 39.6
months and 37.0% in patients with CLM resected after
PCT, most of which were administered as front-line
regimen [11]. The survival rates in our patients are
consistent with these results.
Compared to chemotherapy alone, a median OS of
58.6 months from diagnosis or 41.4 months from hep-
atectomy following a second-line regimen is quite
promising for patients failing a first-line regimen. A
recent Phase III trial reported a median OS from ran-
domisation of 13.5 months in patients receiving second-
line therapy of aflibercept added to an irinotecan-based
regimen [12]. Another trial combining bevacizumab with
irinotecan- or oxaliplatin-based second-line reported a
median OS from the start of first-line of 23.9 months
[13]. In this context, our results support the indication ofCLM resection even after second-line regimen, when-
ever technically possible.
Furthermore, even though the risk of surgery after
second-line chemotherapy was expected to be increased
owing to the larger number of cycles and the heavier
tumour load, we found that the 90-d mortality in group
2 was similar to that in group 1 (<3%). These results
are also consistent with recent data reporting a median
30-d mortality of 2.8% in CLM treated with hepatec-
tomy irrespective of PCT delivery [14]. Compared to
that of group 1, the risk appeared nevertheless
acceptable, with no increased mortality and with more
frequent but tolerable morbidity (33.5% versus 29.9%),
further endorsing resection whenever indicated after
second-line PCT.
In addition, our rather large sample size allowed the
identification of prognostic factors, allowing an even
more refined selection of patients in second-line PCT
concerning the indication of surgery (Table 2). In the
multivariate model of group 2, metastatic primary
lymph nodes, concomitant extrahepatic disease, and R2
liver resection were independently associated with a
decreased OS. However, the required surgical proced-
ures including major hepatectomy, two-stage
hepatectomy or repeat hepatectomies did not emerge
as independent prognostic factors. As expected, tumour
progression on second-line emerged independently as a
negative factor for OS in multivariate model. This sug-
gests that control of the disease, particularly for second-
line PCT patients, is essential before surgery to improve
outcome, as previously reported by our team in a study
on patients with >3 metastases [15]. Additionally, the
reason for discontinuation of first-line and switching to
second-line was believed to be relevant to the outcome,
especially progression as a surrogate for a more bio-
logically resistant and aggressive disease.
R. Adam et al. / European Journal of Cancer 78 (2017) 7e1514Discontinuation for unacceptable toxicity is a common
reason for quitting a clinical trial. Even though disease
progression is the most frequent cause of discontinua-
tion, basically every oncologist has had experience of
switch to second-line for poor tolerance. Therefore, we
included such patients receiving second-line because of
toxicity. In this study, the causes were exhibited as not
only progression (22.2%) but stable disease, insufficient
partial response or intolerable toxicity (7.0%). However,
the occurrence of progression during the first-line did
not independently impact on OS after diagnosis, on the
condition that the disease was favourably controlled by
second-line PCT, and patients achieved to be resected.
This finding proposes an effective treatment of second-
line even when the disease appeared chemo-resistant to
front-line.
Multivariate analysis showed that metastatic primary
lymph nodes, synchronous and bilateral metastases were
significantly associated with a decreased DFS in group 2
patients. To our knowledge, no study has yet reported
prognostic factors of DFS on such patients. Among all
patients with resected CLM, reported DFS predictors
include primary lymph nodes, number of liver metas-
tases, resection margin and CA19-9 after hepatectomy
[16e18]. We found that the type of regimen, the use of
biological agents, the number of cycles and a tumour
progression on PCT were not associated with DFS.
Moreover, initially unresectable patients did not suffer a
poorer OS or DFS than those initially resectable,
although the definition of unresectability could have
differed from one centre to another.
Among initially unresectable patients with CLM
resected after a second-line regimen, encouragingly, OS
or DFS was comparable to its counterpart among the
patients after first-line. The 3-year OS after diagnosis of
45% in this study compares favourably to that of 10%e
44% reported in series of conversion therapies with
targeted agents or of hepatic arterial infusion after
failure of previous regimens [19e21].
The current study has obviously some limitations. It
is a retrospective analysis of surgery-based database
with evitable selection bias. By definition the patients
who eventually did not undergo resection were not
evaluated in LiverMetSurvey. Also, the chemotherapy
regimens were decided at the convenience of local on-
cologists and were consequently diverse, and the treat-
ment algorithms were non-standardised. But on the
other hand, this study presents the ‘real life’ results of a
large international cohort, acknowledging that the
evaluation of such an approach would be difficult in
small series of individual centres and unpractical to be
designed within a randomised clinical trial. Further-
more, the heterogeneity of PCT regimens used allowed a
comparison among them. Thus, in accordance with
previous [7] and more recent [22,23] reports, neither the
cytotoxic backbone (oxaliplatin or irinotecan), nor the
targeted agent (anti-VEGF or anti-EGFR) used forsecond-line in this study impacted on clinical outcomes,
provided that they were active in downsizing the disease
and achieving resectability.
In conclusion, our study demonstrated that CLM
resection after second-line chemotherapy, once it is
achieved with favourable disease control, even with le-
sions deemed initially as non-resectable, could offer an
estimated survival close to that after first-line and better
than what is proved by concomitant data on chemo-
therapy alone, without a higher risk of perioperative
mortality. Hence, we propose liver surgery on the pa-
tients whose liver metastases are sufficiently downsized
to envisage resection, not only after front-line but also
after active salvage chemotherapy.
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